Case closed: Neutrons settle 40-year debate on enzyme for drug design
Filter News
Area of Research
News Topics
- (-) Biomedical (2)
- (-) Physics (1)
- 3-D Printing/Advanced Manufacturing (4)
- Advanced Reactors (7)
- Bioenergy (1)
- Computer Science (2)
- Coronavirus (1)
- Decarbonization (1)
- Fusion (6)
- Isotopes (5)
- Materials Science (2)
- Molten Salt (4)
- Neutron Science (3)
- Nuclear Energy (21)
- Space Exploration (2)
- Sustainable Energy (1)
- Transformational Challenge Reactor (3)
Media Contacts
Oak Ridge National Laboratory researchers have discovered a better way to separate actinium-227, a rare isotope essential for an FDA-approved cancer treatment.
As a teenager, Kat Royston had a lot of questions. Then an advanced-placement class in physics convinced her all the answers were out there.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.